Karyopharm Therapeutics Inc. reports material agreement in SEC 8-K

Karyopharm Therapeutics Inc. filed an 8-K covering a material definitive agreement, SEC Item 1.03, a direct financial obligation, and a triggering event affecting a financial obligation. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.